CUSIP: 89620X506
Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
6,958,612
-
Share change
-
-52,891
-
Total reported value
-
$40,344,367
-
Price per share
-
$5.80
-
Number of holders
-
25
-
Value change
-
-$310,482
-
Number of buys
-
7
-
Number of sells
-
11
Quarterly Holders Quick Answers
What is CUSIP 89620X506?
CUSIP 89620X506 identifies 89620X506 - TRILLIUM THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2018
-
Previous quarter:
Q2 2018
Recent filing periods for CUSIP 89620X506:
Institutional Holders of TRILLIUM THERAPEUTICS INC - COM NEW as of Q3 2018
As of 30 Sep 2018,
TRILLIUM THERAPEUTICS INC - COM NEW was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,958,612 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, AWM Investment Company, Inc., BAKER BROS. ADVISORS LP, Cormorant Asset Management, LP, Tekla Capital Management LLC, MORGAN STANLEY, PLATINUM INVESTMENT MANAGEMENT LTD, Artal Group S.A., and Stanley-Laman Group, Ltd..
This page lists
25
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.